Wednesday, September 27, 2006
FDA Approves Amgen's Vectibix
The U.S. Food and Drug Administration said Wednesday that the agency has approved Thousand Oaks-based Amgen's Vectibix treatment for colorectal cancer. Vectibix is a human monoclonal antibody for treatment of patients with epidermal growth factor receptor-(EGFr) expressing metastatic colorectal cancer. Amgen said that Vectibix is expected to be commercially availabile in early to mid October. Vectibix is expected to compete with Erbitux, a drug from ImClone Systems.